Clinical trials: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Condition Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Non-Small-Cell Lung Carcinoma
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred…
- Trial name
- NCT00404924
- Testing
- ZD6474 (vandetanib), Best Supportive Care
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 1,140 people
- Sponsor
- Genzyme, a Sanofi Company
Non-Squamous Non-Small Cell Lung Cancer
PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line…
- Trial name
- NCT01659970
- Where
- 110 sites in France
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents.
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Trial name
- NCT06561685
- Testing
- LY4050784, Pembrolizumab, Cisplatin
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Squamous NSCLC
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC
- Trial name
- NCT03629925
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 357 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-small Cell Lung Cancer
Phase 3 Clinical Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer…
- Trial name
- NCT05184712
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Akeso
Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
This is a Phase 1/2, open-label, multi-center study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-929 in participants with advanced solid tumors harboring a Kirsten rat sarcoma viral oncogene…
- Conditions
- Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer, Endometrial Adenocarcinoma
- Trial name
- NCT07912593
- Testing
- ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- Ensem Therapeutics
Adenocarcinoma of Lung
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
To demonstrate that CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period
- Trial name
- NCT03676192
- Testing
- CT-P16, Avastin
- Where
- South Korea
- Volunteers
- 689 people
- Sponsor
- Celltrion
Advanced Solid Tumor, Cutaneous Tumor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed…
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
- Trial name
- ANCHOR (NCT06171750)
- Testing
- tolododekin alfa, Cemiplimab
- Where
- 5 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Ankyra Therapeutics, Inc
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
Non-small-cell Lung Cancer
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT01138163
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 121 people
- Sponsor
- Peregrine Pharmaceuticals
Non Small Cell Lung Cancer
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT05513703
- Testing
- Telisotuzumab Vedotin
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 9 people
- Sponsor
- AbbVie
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Non-Squamous Non-Small Cell Lung Cancer
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
This open-label, multicenter, non-randomized, dose-escalating phase Ib study with an expansion cohort will determine the recommended Phase II dose and schedule to investigate safety, tolerability, and activity of RO5083945 in…
- Trial name
- NCT01702714
- Testing
- RO5083945, carboplatin, cisplatin
- Sponsor
- Hoffmann-La Roche
Squamous Cell Non-small Cell Lung Cancer
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
- Trial name
- NCT01642004
- Testing
- Nivolumab, Docetaxel
- Where
- 127 sites in United States, Argentina and 19 more
- Volunteers
- 272 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Squamous Non-small Cell Lung Cancer
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second…
- Trial name
- NCT04552535
- Testing
- Second line (2L) afatinib, Second line chemotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Advanced Non Small Cell Lung Cancer (NSCLC)
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.
- Trial name
- NCT01646125
- Testing
- AUY922, Docetaxel, Pemetrexed
- Where
- 27 sites in United States, France and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
- Trial name
- NCT03802240
- Testing
- Sintilimab, IBI305, Pemetrexed
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.